Healthcare capital for South East Asia's next decade.
Our Singapore platform anchors South East Asian coverage — backing biotech and MedTech originators, diagnostics and hospital networks, and HealthTech businesses across Singapore, Indonesia, Vietnam, Malaysia, Thailand and the Philippines with concentrated cheques from US$10 million.
What we fund across South East Asia
Biotech and therapeutics originated in Singapore's research base, including AI-assisted discovery platforms and translational programmes with credible international regulatory pathways.
MedTech, devices and diagnostics networks built for high-volume, cost-sensitive delivery — decentralised testing, imaging and point-of-care platforms that lower cost per patient across the archipelago economies.
Hospital and specialty-care platforms, pharmaceutical and device manufacturing serving regional demand, and HealthTech businesses with real unit economics rather than subsidised growth.
Why South East Asia, and why now
ASEAN combines a 680-million-person population, rapidly rising insurance and public-scheme coverage, and a manufacturing base that is being deliberately re-shored for medicines and devices. Clinical demand is converting into fundable, payer-backed revenue rather than aid-dependent volume.
Singapore supplies the science, capital and regulatory credibility; Indonesia, Vietnam, the Philippines, Malaysia and Thailand supply the scale. Companies that pair the two are exactly the profile our concentrated, capped-portfolio model is designed to underwrite.
How we work with founders in the region
A Singapore office with partners on the ground, plus India-based manufacturing, CDMO and clinical relationships that regional companies can access directly rather than build alone.
Support across regulatory strategy (HSA, NMPA-adjacent and FDA pathways), cross-border market entry, senior hiring and downstream capital introductions to Gulf and US investors.
Frequently asked questions
- Does OceansGled invest in South East Asian healthcare companies?
- Yes. Our Singapore platform covers Singapore, Indonesia, Vietnam, Malaysia, Thailand and the Philippines, investing in biotech, MedTech, diagnostics, hospital platforms and HealthTech.
- What kinds of South East Asian companies qualify?
- Companies past product readiness with initial market validation that can absorb a minimum US$10 million cheque at Series A or Series B, with reserved follow-on capital for later rounds.
- Can institutional investors co-invest in South East Asia alongside OceansGled?
- Yes. Co-investment vehicles and SPVs are available to qualified institutional partners; write to contact@oceansgled.com to begin a conversation.